• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

    9/8/25 5:57:34 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email

    NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the "Offering") of $250.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering is expected to close on September 12, 2025, subject to customary closing conditions.

    The 2030 Notes will bear interest at the rate of 8.625% per year. Interest on the 2030 Notes will be payable semi-annually in arrears on March 15 and September 15 of each year, commencing on March 15, 2026. The 2030 Notes will mature on September 15, 2030. The 2030 Notes were offered at a price of 100% of the principal amount.

    The Company expects to use the net proceeds from the Offering to repay in full its $107.5 million facility with Oaktree Fund Administration, LLC, as administrative agent to the lenders thereunder, to redeem in full the $75.0 million aggregate principal amount of its outstanding 8.625% Senior Notes (HROWL) (the "2026 Notes"), and the $40.25 million aggregate principal amount of its outstanding 11.875% Senior Notes (HROWM) (the "2027 Notes"), and to pay certain exit costs related thereto. Any remaining proceeds are expected to be used for general corporate purposes, which may include funding future strategic business development opportunities and related investments.

    The 2030 Notes and the related guarantees have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the 2030 Notes and the related guarantees are being offered only to persons reasonably believed to be "qualified institutional buyers," as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-"U.S. persons" in accordance with Regulation S under the Securities Act.

    A confidential offering memorandum for the Offering, dated as of today, is being made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

    This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, or solicitation to buy, if at all, will be made only by means of a confidential offering memorandum. This press release does not constitute a notice of repayment or notice of redemption of outstanding indebtedness, or an offer or solicitation to purchase the 2026 Notes, the 2027 Notes or any other security.

    About Harrow

    Harrow, Inc. (NASDAQ:HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including, without limitation, statements regarding the Offering, the expected use of proceeds of the Offering, including the redemption of outstanding senior notes, and prepayment of the Oaktree facility, and the expected closing date of the Offering. These statements are based on currently available operating, financial, economic and other information, and are subject to a number of significant risks and uncertainties. A variety of factors, many of which are beyond our control, could cause actual future results to differ materially from those projected in the forward-looking statements. Specific factors that might cause such a difference include, but are not limited to: changes in market conditions, negotiation of final transaction documents, changes in operations, business, financial or other conditions relevant to the planned transactions, and other execution risks related to the completion of the transactions described herein, as well as other risks detailed in our most recent annual report on Form 10-K and other filings with the Securities and Exchange Commission. We believe these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Furthermore, forward-looking statements speak only as of the date they are made. If any of these risks or uncertainties materialize, or if any of our underlying assumptions are incorrect, we may not be able to complete the potential transactions on terms expected or at all, and our actual results may differ significantly from those expected or implied by our forward-looking statements. These and other risks are detailed in our filings with the Securities and Exchange Commission. We do not undertake any obligation to publicly update or revise these forward-looking statements after the date of this press release to reflect future events or circumstances, except as required by applicable law. We qualify any and all of our forward-looking statements by these cautionary factors.

    Contact:

    Mike Biega

    Vice President of Investor Relations and Communications

    [email protected]

    617-913-8890



    Primary Logo

    Get the next $HROW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    6/12/2025$62.00Buy
    BTIG Research
    6/10/2025Outperform
    William Blair
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    More analyst ratings

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/25/24 5:19:24 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/24/24 4:40:20 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/19/24 6:24:32 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Pollard Randall E.

    4 - HARROW, INC. (0001360214) (Issuer)

    9/9/25 9:07:57 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Pollard Randall E.

    3 - HARROW, INC. (0001360214) (Issuer)

    9/9/25 9:04:56 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Baum Mark L covered exercise/tax liability with 313,338 shares and exercised 600,000 shares at a strike of $7.87, increasing direct ownership by 11% to 2,886,124 units (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    7/23/25 9:10:48 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harrow to Acquire Melt Pharmaceuticals

    NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and Harrow-affiliated parties. Melt's lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of a fixed dose o

    9/26/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Launches Harrow Access for All (HAFA)

    HAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All ("HAFA"), expanding Harrow's commitment to make it easier and more affordable for patients to access Harrow's full range of branded, generic, and compounded ophthalmic medications. HAFA builds on the success of the VEVYE® Access for All ("VAFA") initiative, which launched in March 2025 with a strong reception from both physician

    9/25/25 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Announces Agenda and Speakers for Investor & Analyst Day

    NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below. Harrow's Investor & Analyst Day will include a comprehensive overview of Harrow's business, featuring presentations from the Company's leadership team covering the full scope of Harrow's commercial portfolio, pipeline, and long-term vision. In addition, the program will include presentations from renowned physici

    9/15/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Harrow with a new price target

    BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

    6/12/25 7:54:43 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Harrow

    William Blair initiated coverage of Harrow with a rating of Outperform

    6/10/25 8:09:06 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    SEC Filings

    View All

    Amendment: Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K/A - HARROW, INC. (0001360214) (Filer)

    10/1/25 7:39:13 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    9/29/25 7:00:47 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    9/26/25 4:05:58 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Leadership Updates

    Live Leadership Updates

    View All

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

    6/18/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

    1/7/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

    Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

    5/13/24 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Financials

    Live finance-specific insights

    View All

    Harrow Announces Second-Quarter 2025 Financial Results

    Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s

    8/11/25 4:01:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

    NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 12, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors" page of Harrow'

    7/29/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. This press release features multimedia. View the full release here: https://www.busin

    6/9/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    10/8/24 6:41:41 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    2/13/24 5:25:53 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care